Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Verinurad Extended-release Formulations
NCT04024501Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of verinurad in chronic kidney disease (CKD) (5 arms), sponsored by AstraZeneca. Primary endpoints: Area Under Plasma Concentration-time Curve From Zero to Infinity, Area Under Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Jul 2019; status: completed.
02
Drugs
verinurad
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04024501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04024501.